JOP20230247A1 - تركيبات وطرق لمعالجة الوهن العضلي الوبيل لدى الأطفال - Google Patents

تركيبات وطرق لمعالجة الوهن العضلي الوبيل لدى الأطفال

Info

Publication number
JOP20230247A1
JOP20230247A1 JOJO/P/2023/0247A JOP20230247A JOP20230247A1 JO P20230247 A1 JOP20230247 A1 JO P20230247A1 JO P20230247 A JOP20230247 A JO P20230247A JO P20230247 A1 JOP20230247 A1 JO P20230247A1
Authority
JO
Jordan
Prior art keywords
methods
myasthenia gravis
children
formulas
treating myasthenia
Prior art date
Application number
JOJO/P/2023/0247A
Other languages
Arabic (ar)
English (en)
Inventor
Shawn Black
Sindhu Ramchandren
Yaowei Zhu
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of JOP20230247A1 publication Critical patent/JOP20230247A1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JOJO/P/2023/0247A 2021-04-12 2023-10-12 تركيبات وطرق لمعالجة الوهن العضلي الوبيل لدى الأطفال JOP20230247A1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163173919P 2021-04-12 2021-04-12
US202163219155P 2021-07-07 2021-07-07
US202263266880P 2022-01-18 2022-01-18
PCT/US2022/024354 WO2022221239A1 (en) 2021-04-12 2022-04-12 Compositions and methods for treating pediatric myasthenia gravis

Publications (1)

Publication Number Publication Date
JOP20230247A1 true JOP20230247A1 (ar) 2023-10-12

Family

ID=83640966

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0247A JOP20230247A1 (ar) 2021-04-12 2023-10-12 تركيبات وطرق لمعالجة الوهن العضلي الوبيل لدى الأطفال

Country Status (13)

Country Link
US (1) US20240182598A1 (https=)
EP (1) EP4323002A4 (https=)
JP (1) JP2024517087A (https=)
KR (1) KR20230169207A (https=)
AU (1) AU2022256389A1 (https=)
BR (1) BR112023021046A2 (https=)
CA (1) CA3216642A1 (https=)
CL (1) CL2023003033A1 (https=)
IL (1) IL307445A (https=)
JO (1) JOP20230247A1 (https=)
MX (1) MX2023012032A (https=)
PH (1) PH12023552841A1 (https=)
WO (1) WO2022221239A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113518783A (zh) 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081144A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
KR102904658B1 (ko) * 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
WO2019160979A1 (en) * 2018-02-13 2019-08-22 The Brigham And Women's Hospital, Inc. Therapeutic fcrn-based bispecific monoclonal antibodies
WO2020023310A1 (en) * 2018-07-20 2020-01-30 Williams Eva Compositions of fcrn antibodies and methods of use thereof

Also Published As

Publication number Publication date
MX2023012032A (es) 2023-12-08
EP4323002A4 (en) 2025-04-16
WO2022221239A1 (en) 2022-10-20
KR20230169207A (ko) 2023-12-15
JP2024517087A (ja) 2024-04-19
BR112023021046A2 (pt) 2023-12-19
AU2022256389A1 (en) 2023-11-30
IL307445A (en) 2023-12-01
CL2023003033A1 (es) 2024-03-08
PH12023552841A1 (en) 2024-05-20
AU2022256389A9 (en) 2023-12-07
CA3216642A1 (en) 2022-10-20
EP4323002A1 (en) 2024-02-21
US20240182598A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
DK202300015Y9 (da) Ikke-animalsk baserede proteinkilder med funktionelle egenskaber
MX2020011694A (es) Composiciones de edulcorante y sabor, metodos de preparacion y metodos de uso de las mismas.
MX2020013169A (es) Conjugados de camptotecina.
WO2020172492A3 (en) Bacterial membrane preparations
CY1122669T1 (el) Σκευασματα αντισωματων αντισκληροστινης υψηλης συγκεντρωσης
MX2023013729A (es) Receptores quimericos de flt3 y metodos de uso de los mismos.
ECSP088924A (es) Anticuerpos e inmunoconjugados y sus usos
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
AR063532A1 (es) Anticuerpos e inmunoconjugados y sus usos
CL2020001442A1 (es) Conjugados anticuerpo anti-cd40-fármaco.
EA202090739A1 (ru) Белки, связывающие антиген созревания в-клеток
JOP20220070A1 (ar) مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها
EP4488286A3 (en) Saccharide-polypeptide conjugate compositions and methods of use thereof
CO2021011906A2 (es) Anticuerpos claudina 6 y usos de los mismos
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
EP2582722A4 (en) ANTIBODIES AGAINST GD2
EA201890895A1 (ru) Мультивалентные и моновалентные мультиспецифические комплексы и их применение
BR112021012631A2 (pt) Anticorpos anti-ctla4 e métodos de uso dos mesmos
DK1784426T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
NO20082658L (no) Fremgangsmåte for behandling av leddskade
MX2023009681A (es) Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon.
ZA202203800B (en) Methods for analysis of viral capsid protein composition
EP4243867A4 (en) Multivalent carriers and related vaccine compositions
JOP20230247A1 (ar) تركيبات وطرق لمعالجة الوهن العضلي الوبيل لدى الأطفال